ArticleAntimicrobial agents and chemotherapy2000
Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 91 citations in OpenAlex.
- A Preliminary Study of the Response ofMolecules (Basel, Switzerland) · 2025Article
- A comprehensive in vitro and in silico assessment of eugenol glycoconjugates against azole and amphotericin B resistant Rhizopus spp.Molecular biology reports · 2025Article
- Anticancer drugs targeting topoisomerase II for antifungal treatment.Scientific reports · 2025Article
- Calcineurin activity in Fonsecaea pedrosoi: tacrolimus and cyclosporine A inhibited conidia growth, filamentation and showed synergism with itraconazole.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Nucleic-Acid-Based Molecular Fungal Diagnostics: A Way to a Better Future.Diagnostics (Basel, Switzerland) · 2024Review
- A promising antifungal lipopeptide from Bacillus subtilis: its characterization and insight into the mode of action.Applied microbiology and biotechnology · 2024Article
- The elucidation of the multimodal action of the investigational anti-Frontiers in molecular biosciences · 2023Article
- Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods.Molecules (Basel, Switzerland) · 2022Review
- Chemical Composition, Antipathogenic and Cytotoxic Activity of the Essential Oil Extracted fromMolecules (Basel, Switzerland) · 2021Article
- Early detection of drug-resistant Streptococcus pneumoniae and Haemophilus influenzae by quantitative flow cytometry.Scientific reports · 2021Article
- Can We Improve Antifungal Susceptibility Testing?Frontiers in cellular and infection microbiology · 2021Review
- Antifungal Susceptibility Testing: Current Approaches.Clinical microbiology reviews · 2020Review
- Frequency ofAdvanced biomedical research · 2020Article
- Review
- Article
- Hydroxychavicol: A phytochemical targeting cutaneous fungal infections.Scientific reports · 2016Article
- Methods forJournal of pharmaceutical analysis · 2016Review
- Susceptibility tests of oropharyngeal Candida albicans from egyptian patients to fluconazole determined by three methods.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2012Article
- Evaluations of shorter exposures of contact lens cleaning solutions against Fusarium oxysporum species complex and Fusarium solani species complex to simulate inappropriate usage.Antimicrobial agents and chemotherapy · 2011Article
- In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?Current infectious disease reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida species other than Candida albicans frequently cause nosocomial infections in immunocompromised patients. Some of these pathogens have either variable susceptibility patterns or intrinsic resistance against common azoles. The availability of a rapid and reproducible susceptibility-testing method is likely to help in the selection of an appropriate regimen for therapy. A flow cytometry (FC) method was used in the present study for susceptibility testing of Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans based on accumulation of the DNA binding dye propidium iodide (PI). The results were compared with MIC results obtained for amphotericin B and fluconazole using the NCCLS broth microdilution method (M27-A). For FC, the yeast inoculum was prepared spectrophotometrically, the drugs were diluted in either RPMI 1640 or yeast nitrogen base containing 1% dextrose, and yeast samples and drug dilutions were incubated with amphotericin B and fluconazole, respectively, for 4 to 6 h. Sodium deoxycholate and PI were added at the end of incubation, and fluorescence was measured with a FACScan flow cytometer (Becton Dickinson). The lowest drug concentration that showed a 50% increase in mean channel fluorescence compared to that of the growth control was designated the MIC. All tests were repeated once. The MICs obtained by FC for all yeast isolates except C. lusitaniae were in very good agreement (within 1 dilution) of the results of the NCCLS broth microdilution method. Paired t test values were not statistically significant (P = 0.377 for amphotericin B; P = 0.383 for fluconazole). Exceptionally, C. lusitaniae isolates showed higher MICs (2 dilutions or more) than in the corresponding NCCLS broth microdilution method for amphotericin B. Overall, FC antifungal susceptibility testing provided rapid, reproducible results that were statistically comparable to those obtained with the NCCLS method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.